Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen del Rocío (15)

2024

  1. ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-related cancer

  2. Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion

    European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 458-466

  3. Glucose metabolism outcomes after pituitary surgery in patients with acromegaly

    Pituitary

  4. Natural history and surgical outcomes of Rathke’s cleft cysts: a Spanish multicenter study

    Frontiers in Endocrinology, Vol. 15

  5. Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-Related Cancer, Vol. 31, Núm. 7

2021

  1. Craniopharyngioma in the Elderly: A Multicenter and Nationwide Study in Spain

    Neuroendocrinology, Vol. 111, Núm. 10, pp. 925-936

  2. The SEEN comprehensive clinical survey of adult obesity: Executive summary

    Endocrinologia, Diabetes y Nutricion, Vol. 68, Núm. 2, pp. 130-136

2020

  1. Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly

    Endocrine, Vol. 70, Núm. 3, pp. 575-583

2019

  1. Treatment adherence to pegvisomant in patients with acromegaly in Spain: PEGASO study

    Pituitary, Vol. 22, Núm. 2, pp. 137-145

2016

  1. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study

    Endocrinología y nutrición: órgano de la Sociedad Española de Endocrinología y Nutrición, Vol. 63, Núm. 8, pp. 397-408

2015

  1. Maternal and Perinatal Outcomes After Bariatric Surgery: a Spanish Multicenter Study

    Obesity Surgery, Vol. 25, Núm. 3, pp. 436-442

2013

  1. Weight-related quality of life in spanish obese subjects suitable for bariatric surgery is lower than in their north american counterparts: A case-control study

    Obesity Surgery, Vol. 23, Núm. 4, pp. 509-514

2002

  1. Effect of withdrawal of somatostatin plus growth hormone (GH)-releasing hormone as a stimulus of GH secretion in Cushing's syndrome

    Clinical Endocrinology, Vol. 57, Núm. 6, pp. 745-749

1999

  1. Regulation of growth hormone secretion by signals produced by the adipose tissue

    Journal of Endocrinological Investigation, Vol. 22, Núm. 5 SUPPL., pp. 22-26

1990

  1. EFFECT OF ENHANCEMENT OF ENDOGENOUS CHOLINERGIC TONE WITH PYRIDOSTIGMINE ON GROWTH HORMONE (GH) RESPONSES TO GH‐RELEASING HORMONE IN PATIENTS WITH CUSHING'S SYNDROME

    Clinical Endocrinology, Vol. 33, Núm. 2, pp. 291-295